IL-31 Blockade Elevates TARC by Lifting LAMP3+ CD1c+ Mature Dendritic Cells from CGRP-CALCRL Neuroimmune Suppression in Atopic Dermatitis - PubMed
3 hours ago
- #dendritic-cells
- #neuroimmune-interactions
- #atopic-dermatitis
- Nemolizumab reduces pruritus and skin lesions in atopic dermatitis (AD) but may cause cutaneous adverse events (CAEs) with increased serum TARC.
- IL-31 receptor A (IL-31RA) blockade elevates TARC levels by disinhibiting a neuroimmune circuit involving CGRP-CALCRL signaling.
- TARC elevation is linked to LAMP3+ CD1c+ mature dendritic cells (DCs), which are suppressed by CGRP signaling from nociceptors.
- IL-31RA blockade removes this suppression, leading to DC maturation and increased TARC production.
- Monitoring TARC and neuroimmune context may help manage AD patients treated with nemolizumab.